Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

الملخص EN

Objectives.

To explore the safety and efficacy profile of teriflunomide in progressive multiple sclerosis.

Methods.

We conducted a single-center retrospective observational analysis of a progressive multiple sclerosis population, assessing safety and efficacy in patients treated at least one year with teriflunomide or glatiramer acetate.

Sustained progression of expanded disability status scale and sustained worsening of timed 25-foot walk were compared using a Cox proportional hazards model.

Results.

Teriflunomide group (n=29) mean characteristics: age=58 years (SD±7.6), disease duration=16.7 years (SD±9.5), expanded disability status score=5.9 (SD±1.3), and follow−up=32.4 months (SD±13.6).

Glatiramer acetate group (n=30) mean characteristics: age=52.4 years (SD±11.3), disease duration=15.1 years (SD±10.4), expanded disability status score=5.7 (SD±1.6), and follow−up=46.9 months (SD±43.9).

Both treatments were well tolerated without serious side effects.

After adjustment for age, sex, and baseline expanded disability status score, sustained expanded disability status score progression did not differ between groups (hazard ratio=1.17; 95% confidence interval: 0.45, 3.08; p=0.75).

Sustained timed 25-foot walk worsening after adjustment also did not differ (hazard ratio=0.56; 95% confidence interval: 0.2, 1.53; p=0.26).

Conclusion.

In an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups.

The small sample precluded definitive determination.